Dr. Garyfalia Karponi Mutations in the epidermal growth factor receptor (EGFR) are among the most important molecular drivers in non-small cell lung cancer (NSCLC). Their prevalence varies significantly depending on geographic region, ethnicity and the clinicopathological characteristics of patients. In Western populations, activating EGFR mutations are detected in approximately 10–15% of patients with NSCLC, while [...]